Comparative Pharmacology
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus ZERBAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus ZERBAXA.
PIPERACILLIN AND TAZOBACTAM vs ZERBAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
Zerbaxa is a combination of ceftolozane, a cephalosporin antibiotic, and tazobactam, a beta-lactamase inhibitor. Ceftolozane inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP3, leading to cell death. Tazobactam protects ceftolozane from degradation by certain beta-lactamases.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours, or 4.5 g (piperacillin 4 g + tazobactam 0.5 g) IV every 8 hours for nosocomial pneumonia.
1.5 g (ceftolozane 1 g + tazobactam 0.5 g) intravenously every 8 hours infused over 1 hour.
None Documented
None Documented
Piperacillin ~0.7–1.2 h, tazobactam ~0.7–1.5 h; prolonged in renal impairment (piperacillin up to 3.3 h, tazobactam up to 5.6 h in severe impairment).
Ceftolozane: ~3 hours; tazobactam: ~1 hour; prolonged in renal impairment.
Primarily renal: piperacillin ~68% unchanged, tazobactam ~80% unchanged; biliary excretion <10%; fecal <1%.
Primarily renal excretion: ceftolozane ~95% unchanged in urine, tazobactam ~80% unchanged in urine; biliary/fecal elimination <1%.
Category C
Category C
Penicillin Antibiotic / Beta-Lactamase Inhibitor Combination
Cephalosporin/Beta-Lactamase Inhibitor Combination